LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year.
2023 Full-Year Highlights
“We were operating in a challenging spending environment given higher interest rates. However, our initiatives enabled us to grow full-year 2023 revenue modestly,” commented John Beaver, President and Chief Executive Officer of BIOLASE. “Our continuing efforts to heighten the interest in our industry-leading dental lasers are driving greater awareness and interest in our award-winning lasers, which we believe will continue in 2024 and allow us to accelerate our revenue growth as we return to a more normalized business climate. The increased utilization of our installed base is a bullish sentiment, as evidenced by the 20% increase in our consumable sales during the year, so our goal is to accelerate growth while continuing to improve our operations. Greater adoption of our dental lasers, coupled with the expansion of our gross margins and lower operating expenses, will allow us to meet our revenue and profitability objectives for 2024.”
2023 Financial Results
Net revenue for the year ended December 31, 2023, was $49.2 million, an increase of 1% compared to net revenue of $48.5 million for the year ended December 31, 2022. U.S. laser revenue was $18.4 million for the year ended December 31, 2023, a decrease of 10% compared to U.S. laser revenue of $20.4 million for the year ended December 31, 2022. U.S. consumables and other revenue for the year ended December 31, 2023, which consists of revenue from consumable products such as disposable tips, increased 31% year over year. International laser revenue was $11.7 million for the year ended December 31, 2023, an increase of 6% compared to $11.0 million for the year ended December 31, 2022. International consumable and other revenue for the year ended December 31, 2023, decreased 3% year over year.
Gross margin for the year ended December 31, 2023, was 34% compared to 33% for the year ended December 31, 2022. Total operating expenses were $34.7 million for the year ended December 31, 2023, compared to $41.2 million for the year ended December 31, 2022, a 16% decrease year over year. Operating loss for the year ended December 31, 2023, was $17.9 million, compared to an operating loss of $25.3 million for the year ended December 31, 2022, a decrease of 29% year over year.
On December 31, 2023, the company had cash and cash equivalents of approximately $6.6 million. Following its February 2024 equity raise of an additional $7.0 million in gross proceeds, the Company believes it has sufficient liquidity to execute its near-term growth strategies and reach positive adjusted EBITDA for the full year 2024.
Net Loss and Adjusted EBITDA
The reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company’s non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company’s Adjusted EBITDA and Adjusted EBITDA per share.
Net loss attributable to common stockholders for the year ended December 31, 2023, was $37.6 million, or $29.44 per share, compared to a net loss of $28.9 million, or $418.13 per share (as adjusted for the reverse stock split), for the year ended December 31, 2022. Adjusted EBITDA for the year ended December 31, 2023, was a loss of $12.8 million, or $10.00 per share, compared with an Adjusted EBITDA loss of $20.1 million, or $291.86 per share (as adjusted for the reverse stock split), for the year ended December 31, 2022.
2024 First Quarter and Full Year Financial Guidance
Conference Call Information
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2023, and to answer questions. To access the live call, dial 1-877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.
A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations page. In addition, a phone replay will be available approximately two hours after the end of the call and will remain available for one week. To access the replay, dial 1-877-344-7529 or +1 412-317-0088 (International) and enter the replay passcode: 3852517.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE’s proprietary laser products incorporate approximately 241 active patents and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE’s expected revenue and revenue growth. Forward-looking statements can be identified through the use of words such as “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, substantial doubt regarding BIOLASE’s ability to continue as a going concern, and those other risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
BIOLASE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
|
|
Three Months Ended | Year Ended | ||||||||||||||
|
|
December 31, | December 31, | ||||||||||||||
|
|
2023 | 2022 | 2023 | 2022 | ||||||||||||
|
Net revenue
|
$ | 13,490 | $ | 14,051 | $ | 49,164 | $ | 48,462 | ||||||||
|
Cost of revenue
|
9,966 | 10,455 | 32,440 | 32,551 | ||||||||||||
|
Gross profit
|
3,524 | 3,596 | 16,724 | 15,911 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Sales and marketing
|
4,227 | 6,451 | 18,441 | 21,675 | ||||||||||||
|
General and administrative
|
2,721 | 3,484 | 10,216 | 12,309 | ||||||||||||
|
Engineering and development
|
1,652 | 2,088 | 6,004 | 7,265 | ||||||||||||
|
Total operating expenses
|
8,600 | 12,023 | 34,661 | 41,249 | ||||||||||||
|
Loss from operations
|
(5,076 | ) | (8,427 | ) | (17,937 | ) | (25,338 | ) | ||||||||
|
Gain (Loss) on foreign currency transactions
|
171 | 114 | (351 | ) | (438 | ) | ||||||||||
|
Interest expense, net
|
(603 | ) | (1,462 | ) | (2,361 | ) | (2,749 | ) | ||||||||
|
Other income, net
|
167 | – | 48 | – | ||||||||||||
|
Non-operating loss, net
|
(265 | ) | (1,348 | ) | (2,664 | ) | (3,187 | ) | ||||||||
|
Loss before income tax benefit (provision)
|
(5,341 | ) | (9,775 | ) | (20,601 | ) | (28,525 | ) | ||||||||
|
Income tax benefit (provision)
|
15 | (86 | ) | (31 | ) | (109 | ) | |||||||||
|
Net loss
|
(5,326 | ) | (9,861 | ) | (20,632 | ) | (28,634 | ) | ||||||||
|
Other comprehensive loss items:
|
||||||||||||||||
|
Foreign currency translation adjustments
|
166 | 305 | 180 | (110 | ) | |||||||||||
|
Comprehensive loss
|
$ | (5,160 | ) | $ | (9,556 | ) | $ | (20,452 | ) | $ | (28,744 | ) | ||||
|
|
||||||||||||||||
|
Net loss
|
$ | (5,326 | ) | $ | (9,861 | ) | $ | (20,632 | ) | $ | (28,634 | ) | ||||
|
Deemed dividend on convertible preferred stock
|
– | – | (16,987 | ) | (217 | ) | ||||||||||
|
Net loss attributable to common stockholders
|
$ | (5,326 | ) | $ | (9,861 | ) | $ | (37,619 | ) | $ | (28,851 | ) | ||||
|
|
||||||||||||||||
|
Net loss per share attributable to common stockholders:
|
||||||||||||||||
|
Basic and Diluted
|
$ | (1.76 | ) | $ | (128.06 | ) | $ | (29.44 | ) | $ | (418.13 | ) | ||||
|
Shares used in the calculation of net loss per share:
|
||||||||||||||||
|
Basic and Diluted
|
3,031 | 77 | 1,278 | 69 | ||||||||||||
BIOLASE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
|
|
December 31, | |||||||
|
|
2023 | 2022 | ||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 6,566 | $ | 4,181 | ||||
|
Accounts receivable, less allowance of $244 and $2,164 as of December 31, 2023 and 2022, respectively
|
5,483 | 5,841 | ||||||
|
Inventory
|
11,433 | 15,884 | ||||||
|
Prepaid expenses and other current assets
|
1,381 | 3,053 | ||||||
|
Total current assets
|
24,863 | 28,959 | ||||||
|
Property, plant, and equipment, net
|
5,525 | 4,278 | ||||||
|
Goodwill
|
2,926 | 2,926 | ||||||
|
Right-of-use assets, leases
|
1,519 | 1,768 | ||||||
|
Other assets
|
268 | 255 | ||||||
|
Total assets
|
$ | 35,101 | $ | 38,186 | ||||
|
LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 6,065 | $ | 5,786 | ||||
|
Accrued liabilities
|
8,881 | 9,210 | ||||||
|
Deferred revenue, current portion
|
2,452 | 2,111 | ||||||
|
Current portion of term loans, net of discount
|
2,265 | 700 | ||||||
|
Total current liabilities
|
19,663 | 17,807 | ||||||
|
Deferred revenue
|
256 | 418 | ||||||
|
Warranty accrual
|
593 | 360 | ||||||
|
Non-current term loans, net of discount
|
11,782 | 13,091 | ||||||
|
Non-current operating lease liability
|
772 | 1,259 | ||||||
|
Other liabilities
|
79 | 362 | ||||||
|
Total liabilities
|
33,145 | 33,297 | ||||||
|
Mezzanine Equity:
|
||||||||
|
Series H Convertible Redeemable Preferred stock, par value $0.001 per share
|
346 | – | ||||||
|
Series J Convertible Redeemable Preferred stock, par value $0.001 per share
|
1,857 | – | ||||||
|
Total mezzanine equity
|
2,203 | – | ||||||
|
Stockholders’ equity (deficit):
|
||||||||
|
Common stock, par value $0.001 per share
|
3 | – | ||||||
|
Additional paid-in capital
|
317,103 | 301,790 | ||||||
|
Accumulated other comprehensive loss
|
(553 | ) | (733 | ) | ||||
|
Accumulated deficit
|
(316,800 | ) | (296,168 | ) | ||||
|
Total stockholders’ equity (deficit)
|
(247 | ) | 4,889 | |||||
|
Total liabilities, convertible redeemable preferred stock and
stockholders’ equity (deficit) |
$ | 35,101 | $ | 38,186 | ||||
BIOLASE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
|
Year Ended | |||||||
|
|
December 31, | |||||||
|
|
2023 | 2022 | ||||||
|
Cash Flows from Operating Activities:
|
||||||||
|
Net loss
|
$ | (20,632 | ) | $ | (28,634 | ) | ||
|
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
|
||||||||
|
Depreciation
|
2,798 | 497 | ||||||
|
Provision for bad debts
|
533 | 40 | ||||||
|
Provision for inventory excess and obsolescence
|
715 | 1,312 | ||||||
|
Inventory write-offs and disposals
|
– | 1,486 | ||||||
|
Amortization of debt issuance costs
|
426 | 1,196 | ||||||
|
Patent litigation mark-to-market
|
– | – | ||||||
|
Change in fair value of warrants
|
(494 | ) | – | |||||
|
Issuance of restricted shares
|
– | 109 | ||||||
|
Issuance costs for warrants
|
447 | – | ||||||
|
Stock-based compensation
|
1,232 | 2,303 | ||||||
|
Gain on disposal of fixed assets
|
(141 | ) | – | |||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
201 | (1,643 | ) | |||||
|
Inventory
|
969 | (5,754 | ) | |||||
|
Prepaid expenses and other current assets
|
1,527 | (1,135 | ) | |||||
|
Accounts payable and accrued liabilities
|
(1,851 | ) | 3,521 | |||||
|
Deferred revenue
|
179 | (59 | ) | |||||
|
Net cash and cash equivalents used in operating activities
|
(14,091 | ) | (26,761 | ) | ||||
|
Cash Flows from Investing Activities:
|
||||||||
|
Purchases of property, plant, and equipment
|
(1,311 | ) | (3,727 | ) | ||||
|
Proceeds from disposal of property, plant, and equipment
|
182 | – | ||||||
|
Net cash and cash equivalents used in investing activities
|
(1,129 | ) | (3,727 | ) | ||||
|
Cash Flows from Financing Activities:
|
||||||||
|
Proceeds from the sale of common stock and pre-funded warrants, net of fees
|
9,553 | 5,602 | ||||||
|
Proceeds from the sale of Convertible Redeemable Preferred Stock, net of fees
|
5,490 | – | ||||||
|
Proceeds from the sale of warrants, net of fees
|
1,743 | – | ||||||
|
Principal payment on loan
|
(165 | ) | (1,000 | ) | ||||
|
Proceeds from the exercise of common stock warrants
|
114 | 1 | ||||||
|
Proceeds from the exercise of preferred share warrants
|
699 | – | ||||||
|
Net cash and cash equivalents provided by financing activities
|
17,434 | 4,603 | ||||||
|
Effect of exchange rate changes
|
171 | (109 | ) | |||||
|
Increase (decrease) in cash and cash equivalents
|
2,385 | (25,994 | ) | |||||
|
Cash, cash equivalents and restricted cash, beginning of year
|
4,181 | 30,175 | ||||||
|
Cash, cash equivalents and restricted cash, end of year
|
$ | 6,566 | $ | 4,181 | ||||
|
Supplemental cash flow disclosure:
|
||||||||
|
Cash paid for interest
|
$ | 1,918 | $ | 1,519 | ||||
|
Cash received for interest
|
$ | 9 | $ | 26 | ||||
|
Cash paid for income taxes
|
$ | 41 | $ | 59 | ||||
|
Cash paid for operating leases
|
$ | 302 | $ | 254 | ||||
|
Non-cash right-of-use assets obtained in exchange for lease obligations
|
$ | 483 | $ | 574 | ||||
|
Deemed dividend on preferred stock
|
$ | – | $ | 217 | ||||
|
Non-cash property, plant and equipment additions acquired under inventory
|
$ | 2,768 | $ | – | ||||
|
Common stock issued upon exercise of preferred stock
|
$ | 22,037 | $ | – | ||||
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net loss before interest, taxes, depreciation, stock-based and other non-cash compensation, severance expense, change in allowance for doubtful accounts, increase in inventory reserves, and other (income) expense, net. Management uses adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC.
Reconciliation of GAAP Net Loss to Adjusted EBITDA and
GAAP Net Loss Per Share to Adjusted EBITDA Per Share
(Unaudited, in thousands, except per share data)
|
|
Three Months Ended | Year Ended | ||||||||||||||
|
|
December 31, | December 31, | ||||||||||||||
|
|
2023 | 2022 | 2023 | 2022 | ||||||||||||
|
GAAP net loss attributable to common stockholders
|
$ | (5,326 | ) | $ | (9,861 | ) | $ | (37,619 | ) | $ | (28,851 | ) | ||||
|
Deemed dividend on convertible preferred stock
|
– | – | 16,987 | 217 | ||||||||||||
|
GAAP net loss
|
$ | (5,326 | ) | $ | (9,861 | ) | $ | (20,632 | ) | $ | (28,634 | ) | ||||
|
Adjustments:
|
||||||||||||||||
|
Interest expense, net
|
603 | 1,462 | 2,361 | 2,749 | ||||||||||||
|
Income tax provision
|
(15 | ) | 86 | 31 | 109 | |||||||||||
|
Depreciation
|
665 | 128 | 2,798 | 497 | ||||||||||||
|
Severance expense
|
6 | – | 236 | – | ||||||||||||
|
Change in allowance for doubtful accounts
|
473 | (16 | ) | 533 | 40 | |||||||||||
|
Stock-based and other non-cash compensation
|
182 | 612 | 1,232 | 2,303 | ||||||||||||
|
Increase in inventory reserve and disposals
|
715 | 1,066 | 715 | 2,798 | ||||||||||||
|
Other income, net
|
(167 | ) | – | (48 | ) | – | ||||||||||
|
Adjusted EBITDA
|
$ | (2,864 | ) | $ | (6,523 | ) | $ | (12,774 | ) | $ | (20,138 | ) | ||||
|
|
||||||||||||||||
|
GAAP net loss attributable to common stockholders per share, basic and diluted
|
$ | (1.76 | ) | $ | (128.06 | ) | $ | (29.44 | ) | $ | (418.13 | ) | ||||
|
Deemed dividend on convertible preferred stock
|
– | – | 13.29 | 3.14 | ||||||||||||
|
GAAP net loss per share, basic and diluted
|
$ | (1.76 | ) | $ | (128.06 | ) | $ | (16.15 | ) | $ | (414.99 | ) | ||||
|
Adjustments:
|
||||||||||||||||
|
Interest expense, net
|
0.20 | 18.99 | 1.85 | 39.84 | ||||||||||||
|
Income tax provision
|
– | 1.12 | 0.02 | 1.58 | ||||||||||||
|
Depreciation
|
0.22 | 1.66 | 2.19 | 7.20 | ||||||||||||
|
Severance expense
|
– | – | 0.18 | – | ||||||||||||
|
Change in allowance for doubtful accounts
|
0.16 | (0.21 | ) | 0.42 | 0.58 | |||||||||||
|
Stock-based and other non-cash compensation
|
0.06 | 7.95 | 0.96 | 33.38 | ||||||||||||
|
Increase in inventory reserve and disposals
|
0.24 | 13.84 | 0.57 | 40.55 | ||||||||||||
|
Other income, net
|
(0.06 | ) | – | (0.04 | ) | – | ||||||||||
|
Adjusted EBITDA per share, basic and diluted
|
$ | (0.94 | ) | $ | (84.71 | ) | $ | (10.00 | ) | $ | (291.86 | ) | ||||
Other income, net for the three and twelve months ended December 31, 2023 relates to issuance costs from the May 2023 public offering that were allocated to the Series H warrants, and issuance costs from the September 2023 public offering that were allocated to the Series J warrants and immediately expensed due to the liability classification of the warrants. These expenses were partially offset by gains recorded on the revaluation of these warrants during the periods.
SOURCE: BIOLASE, Inc.
View the original press release on accesswire.com
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION…
LUND, SE / ACCESSWIRE / June 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…
GOTHENBURG, SWEDEN / ACCESSWIRE / June 11, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, June…
NO FEDERAL MARIJUANA IS BEING GROWNMMJ Marijuana Researcher Calls Biden's DEA a Rogue Law Enforcement…
SUZHOU, China, and ROCKVILLE, Md., June 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global…
GRESHAM, Ore. and TOKYO , June 10, 2024 /PRNewswire/ -- Element Six (E6) and Orbray, both…